Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
LNSR 
LENSAR Inc (LNSR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: LNSR (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $15
1 Year Target Price $15
| 0 | Strong Buy |
| 0 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 118.26% | Avg. Invested days 48 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 148.83M USD | Price to earnings Ratio - | 1Y Target Price 15 |
Price to earnings Ratio - | 1Y Target Price 15 | ||
Volume (30-day avg) 2 | Beta 0.49 | 52 Weeks Range 3.80 - 17.31 | Updated Date 09/14/2025 |
52 Weeks Range 3.80 - 17.31 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.21 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -84.49% | Operating Margin (TTM) -15.18% |
Management Effectiveness
Return on Assets (TTM) -7.19% | Return on Equity (TTM) -350.22% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 130849756 | Price to Sales(TTM) 2.55 |
Enterprise Value 130849756 | Price to Sales(TTM) 2.55 | ||
Enterprise Value to Revenue 2.24 | Enterprise Value to EBITDA -1.04 | Shares Outstanding 11934800 | Shares Floating 8637800 |
Shares Outstanding 11934800 | Shares Floating 8637800 | ||
Percent Insiders 19.41 | Percent Institutions 47.86 |
Upturn AI SWOT
LENSAR Inc
Company Overview
History and Background
LENSAR, Inc. is a global medical technology company focused on femtosecond laser technology for refractive cataract surgery. Founded in 2004, it developed and commercialized the LENSAR Laser System. The company has evolved from focusing solely on cataract surgery to exploring other ophthalmic applications.
Core Business Areas
- Cataract Surgery: Development, manufacturing, and sales of femtosecond laser systems used in cataract surgery. The LENSAR Laser System helps surgeons improve accuracy and precision during key steps of the cataract procedure.
Leadership and Structure
LENSAR's leadership includes its CEO, CFO, and other key executives. The company has a board of directors overseeing its operations. The organizational structure is typical of a publicly traded medical device company, with departments for R&D, manufacturing, sales, marketing, and finance.
Top Products and Market Share
Key Offerings
- LENSAR Laser System: A femtosecond laser platform used for cataract surgery, offering features such as augmented reality imaging and advanced segmentation capabilities. Market share data is difficult to obtain precisely as it is split up into regions and laser platforms. Competitors include Alcon, Johnson & Johnson Vision, and Bausch + Lomb.
Market Dynamics
Industry Overview
The ophthalmic surgical market is growing due to an aging population and increasing prevalence of cataracts. Technological advancements like femtosecond lasers are driving demand for more precise and efficient surgical solutions.
Positioning
LENSAR aims to position itself as a provider of advanced laser technology for cataract surgery, differentiating itself through its augmented reality imaging and precision capabilities.
Total Addressable Market (TAM)
The global ophthalmic surgery market is estimated to be in the billions of dollars. LENSAR's TAM is a portion of this, specifically focused on femtosecond laser cataract surgery. LENSAR is positioned to capture a share of this market with its advanced technology.
Upturn SWOT Analysis
Strengths
- Advanced femtosecond laser technology
- Augmented reality imaging capabilities
- Precision and accuracy in cataract surgery
- Proprietary technology portfolio
Weaknesses
- Limited product portfolio compared to larger competitors
- High cost of equipment may limit market access
- Dependence on a single core product (LENSAR Laser System)
- Requires specialized training for surgeons
Opportunities
- Expanding into new ophthalmic applications (e.g., refractive surgery)
- Increasing market penetration in emerging economies
- Developing partnerships with ophthalmic clinics and hospitals
- Further technological innovation to enhance laser precision
Threats
- Competition from larger medical device companies
- Reimbursement challenges and healthcare cost pressures
- Technological obsolescence
- Economic downturns affecting capital equipment spending
Competitors and Market Share
Key Competitors
- ALC
- JNJ
- BHC
Competitive Landscape
LENSAR faces intense competition from larger, more established companies with broader product portfolios. LENSAR's competitive advantage lies in its advanced laser technology, but it needs to overcome its smaller size and limited resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth depends on the growth of sales of the LENSAR Laser System and related consumables.
Future Projections: Future growth depends on the company's ability to expand its market share, innovate its products, and enter new markets. Analyst estimates would provide specific projections.
Recent Initiatives: Recent initiatives include product enhancements, expanding sales channels, and exploring new applications for its laser technology.
Summary
LENSAR Inc. is a medical technology company focused on femtosecond laser cataract surgery. The company's strength lies in its advanced technology, but it faces challenges from larger competitors. Key areas for focus include expanding market share, innovating new products, and managing costs. LENSAR needs to be aware of the potential for technological obsolescence and economic downturns impacting capital equipment spending, but continued innovation should propel the company forward.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- Industry Reports
- Analyst Reports (if available)
Disclaimers:
The data and analysis provided are based on available information and are subject to change. Market share data is approximate and based on industry estimates. This is not financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About LENSAR Inc
Exchange NASDAQ | Headquaters Orlando, FL, United States | ||
IPO Launch date 2020-10-02 | President, CEO & Director Mr. Nicholas T. Curtis | ||
Sector Healthcare | Industry Medical Devices | Full time employees 140 | Website https://www.lensar.com |
Full time employees 140 | Website https://www.lensar.com | ||
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System. The company offers LENSAR Laser System which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision. It also provides ALLY Robotic Cataract Laser System, a compact cataract treatment system that is designed to allow surgeons to perform sterile laser-assisted cataract surgery in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.